文献速递外周动脉疾病

肝病与腹股沟下旁路术后死亡和主要并发症增加相关,但血管内介入术后不相关

Liver Disease is Associated with Increased Mortality and Major Morbidity After Infra-Inguinal Bypass but not After Endovascular Intervention.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2021-03-24

基于NSQIP 2005-2016数据,腹股沟下旁路术17 603例和血管内介入7 830例,用APRI>0.5定义肝纤维化。肝纤维化与旁路术后30天死亡率和主要并发症升高相关且多变量调整后持续,MELD>15者旁路术后结局更差;血管内介入后仅肾并发症在调整后持续。

要点

  • 肝纤维化(APRI>0.5)与腹股沟下旁路术后30天死亡和主要并发症升高独立相关。
  • 肝纤维化患者MELD>15时旁路术后死亡率和并发症进一步升高。
  • 血管内介入后肝纤维化仅与肾并发症独立相关,建议肝纤维化患者可优先考虑血管内治疗。

核心结论

  • 肝纤维化与腹股沟下旁路术后30天死亡率和主要并发症升高相关,且MELD评分升高时结局更差。
  • 肝纤维化与血管内介入术后30天死亡率、肺和肾并发症相关,但多变量调整后仅肾并发症持续。
  • 肝纤维化患者管理外周动脉疾病时可考虑血管内优先策略。

研究设计与样本

  • 回顾性队列研究,使用美国国家手术质量改进计划(NSQIP)2005-2016年数据。
  • 纳入腹股沟下旁路术患者17 603例和血管内介入患者7 830例。
  • 用APRI评分>0.5定义肝纤维化,比较有无肝纤维化患者的人口学、合并症和30天结局。
  • 对APRI>0.5患者按MELD评分进行亚组分析,多变量回归调整基线差异。

主要发现

  • 旁路术后,肝纤维化患者死亡率3.8% vs. 2.4%(p < .001),主要并发症23% vs. 20%(p = .020)。
  • 旁路术后,肝纤维化患者肺部并发症5.1% vs. 2.9%(p < .001),肾脏并发症1.9% vs. 1.1%(p = .007)。
  • 血管内介入后,肝纤维化患者死亡率4.7% vs. 2.2%(p < .001),肺部并发症3.9% vs. 2.5%(p = .022),肾脏并发症1.9% vs. 0.8%(p = .003)。
  • 多变量调整后,旁路术后差异持续;血管内介入后仅肾脏并发症持续。
  • 肝纤维化患者中,MELD>15者旁路术后并发症31% vs. 17%(p < .001),死亡率7.2% vs. 1.8%(p < .001),血管内介入后无此差异。

关键数值与推荐

  • APRI评分>0.5定义为肝纤维化。
  • MELD评分>15用于亚组分析评估结局恶化。

临床怎么用

  • 肝纤维化患者行腹股沟下旁路术前应充分评估风险,尤其MELD>15者。
  • 肝纤维化患者管理外周动脉疾病时可优先考虑血管内介入以降低死亡和主要并发症风险。
  • 血管内介入后仍需关注肾功能并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Liver disease increases mortality after abdominal surgery, including endovascular aortic aneurysm repair. However, its effect on mortality and morbidity after endovascular and open management of peripheral vascular disease has not been widely evaluated. METHODS: The National Surgical Quality Improvement Program was used to evaluate patients undergoing infra-inguinal bypass and endovascular intervention (2005 - 2016). Aspartate aminotransferase to platelet ratio (APRI score) is a non-invasive tool recommended by the World Health Organisation to identify liver disease and was calculated for all patients. A ratio of > 0.5 was used to identify patients with liver fibrosis. Demographics, comorbidities, and 30 day outcomes were evaluated for patients with and without liver fibrosis. A subgroup analysis was completed in patients with APRI scores > 0.5, to evaluate the effect of increasing Model for End-Stage Liver Disease (MELD) scores on outcomes. Multivariable regression was used to account for differences in baseline factors. RESULTS: In total, 17 603 patients underwent infra-inguinal bypasses. Fibrosis was associated with higher mortality (3.8% vs. 2.4%; p < .001), major complications (23% vs. 20%; p = .020), pulmonary (5.1% vs. 2.9%; p < .001), and renal complications (1.9% vs. 1.1%; p = .007) after bypass. These differences persisted following multivariable adjustment. Altogether, 7 830 patients underwent endovascular intervention. Fibrosis was also associated with higher mortality (4.7% vs. 2.2%; p < .001), pulmonary (3.9% vs. 2.5%; p = .022), and renal complications (1.9% vs. 0.8%; p = .003) after endovascular intervention. After adjustment, only renal complications persisted. In a subgroup analysis of patients with liver fibrosis, morbidity (31% vs. 17%; p < .001) and mortality (7.2% vs. 1.8%; p < .001) increased after bypass among those with MELD scores > 15 but not after endovascular intervention. CONCLUSION: Liver fibrosis was associated with higher 30 day mortality and major complications after infra-inguinal bypass, with outcomes worsening as MELD scores increased. Surgeons may consider an endovascular first approach in managing peripheral arterial disease among those with liver fibrosis.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Zettervall SL, Dansey K, Evenson A, et al. Liver Disease is Associated with Increased Mortality and Major Morbidity After Infra-Inguinal Bypass but not After Endovascular Intervention. Eur J Vasc Endovasc Surg. 2021. PMID: 33773904. doi:10.1016/j.ejvs.2021.02.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。